Sur1M2

Sur1M2 is a **modified peptide derived from survivin (BIRC5)**, a protein highly expressed in many cancers and associated with inhibition of apoptosis. Sur1M2 is designed to act as a cancer vaccine antigen, specifically capable of inducing **CD8+ T-cell responses**. The primary mechanism is the induction of cellular and humoral immune responses directed against survivin-expressing tumor cells, enabling immune-mediated anti-tumor activity. Sur1M2 has been tested both in vitro and in clinical settings for its immunogenic properties and as part of peptide vaccination strategies in metastatic melanoma and other survivin-expressing cancers[2][6][7][10].

Other names

survivin Sur1M2 peptide vaccine